Subscribe To

Price Alert Latest News Economic Calendar News

AVEO / AVEO Oncology Announces Participation at Investor Conferences in September

BOSTON, Aug. 31, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, today announced that members of its senior management team are scheduled to participate in three investor conferences in September, including: Read More

Demo Live Account See Partner Details

Content Topics

AVEO

Oncology

Announces

Participation

Investor

Conferences

September

Stock

Posted: Aug 31 2022, 08:30

Author Name: GlobeNewsWire

AVEO News

By Zacks Investment Research
December 26, 2022

Are Medical Stocks Lagging AVEO Pharmaceuticals (AVEO) This Year?

Here is how AVEO Pharmaceuticals (AVEO) and Merit Medical (MMSI) have performed compared to their sector so far this year.

By Zacks Investment Research
November 21, 2022

AVEO Oncology (AVEO): Strong Industry, Solid Earnings Estimate Revisions

AVEO Oncology (AVEO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

By Zacks Investment Research
November 7, 2022

AVEO Pharmaceuticals (AVEO) Reports Q3 Loss, Tops Revenue Estimates

AVEO (AVEO) delivered earnings and revenue surprises of 43.75% and 1.67%, respectively, for the quarter ended September 2022. Do the numbers hold clue

By GlobeNewsWire
August 31, 2022

AVEO Oncology Announces Participation at Investor Conferences in September

BOSTON, Aug. 31, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to de

By Zacks Investment Research
August 29, 2022

Here's Why AVEO Pharmaceuticals (AVEO) is a Great Momentum Stock to Buy

Does AVEO Pharmaceuticals (AVEO) have what it takes to be a top stock pick for momentum investors? Let's find out.

By Zacks Investment Research
August 26, 2022

What Makes AVEO (AVEO) a Good Fit for "Trend Investing"

AVEO (AVEO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are

By Seeking Alpha
August 4, 2022

AVEO Pharmaceuticals, Inc. (AVEO) CEO Michael Bailey on Q2 2022 Results - Earnings Call Transcript

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Hans Vitzthum - LifeSci Advi

By Seeking Alpha
May 5, 2022

AVEO Pharmaceuticals' (AVEO) CEO Michael Bailey on Q1 2022 Results - Earnings Call Transcript

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO ) Q1 2022 Earnings Conference Call May 5, 2022 8:00 AM ET Company Participants Hans Vitzthum – LifeSci Advis

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.